IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(6):1060-1067

Original Article
KAI1/CD82 and CyclinD1 as biomarkers of invasion, metastasis and prognosis of
laryngeal squamous cell carcinoma

Binghui Zhang, Wei Liu, Liang Li, Jianguang Lu, Ming Liu, Yanan Sun, Dejun Jin

Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, P. R. China;
Experiment Center, Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, P. R. China

Received March 25, 2013; Accepted April 23, 2013; Epub May 15, 2013; Published June 1, 2013

Abstract: Objective: This study aimed to investigate the expressions and significance of KAI1/CD82 and CyclinD1 in laryngeal squamous cell
carcinoma (LSCC). Methods: Real-time quantitative PCR (Q-PCR) and Western blot assay were employed to detect the expressions of
KAI1/CD82 and CyclinD1 in the laryngeal tissues of 86 LSCC patients, 32 patients with laryngeal polyp and 38 patients with laryngeal
leukoplakia, and the influence of both proteins on the clinicopathological features and survival of LSCC patients. Results: The changes in
mRNA and protein expressions of KAI1/CD82 and CyclinD1 were consistent in three groups, and the expressions of KAI1/CD82 and CyclinD1
were significantly different among three groups (P<0.01 or <0.05). The KAI1/CD82 expression in patients with TNM stage III-IV LSCC, poorly
differentiated LSCC, clinical stage III-IV LSCC or lymph node metastasis was markedly lower than that in those with TNM stage I-II LSCC, well
differentiated LSCC, clinical stage I-II LSCC or no lymph node metastasis (P<0.01 or <0.05). However, there was no marked difference in
KAI1/CD82 expression between males and females and among patients in different age groups (P>0.05). In LSCC patients positive for
KAI1/CD82 protein expression, the median survival time was 76 months, which was significantly longer than that in LSCC patients negative for
KAI1/CD82 protein expression (48 months; X2=16.293, P=0.000). The CyclinD1 expression in patients with TNM stage III-IV LSCC, poorly
differentiated LSCC, or clinical stage III-IV LSCC was dramatically higher than that in patients with TNM stage I-II LSCC, well differentiated
LSCC, or clinical stage I-II LSCC (P<0.01 or <0.05). However, no marked difference was noted in CyclinD1 expression between males and
females, among patients in different age groups and between patients with and without lymph node metastasis (P>0.05). In LSCC patients
positive for CyclinD1 protein expression, the median survival time was 40 months, which was markedly shorter than that in LSCC patients
negative for CyclinD1 protein expression (X2=9.517, P=0.02). In LSCC patients, there was a negative correlation between KAI1/CD82
expression and CyclinD1 expression (X2=7.86, P<0.01). Conclusion: KAI1/CD82 affects cell cycle. Both KAI1/CD82 and CyclinD1 are involved in
the occurrence and development of LSCC, and may provide clinical information for evaluation of invasiveness, metastasis and prognosis of
LSCC. Thus, KAI1/CD82 and CyclinD1 may serve as markers for determination of invasiveness, metastasis and prognosis of LSCC.
(IJCEP1303052).

Keywords: Laryngeal squamous cell carcinoma, KAI1/CD82, CyclinD1

Address correspondence to: Dejun Jin, Department of Otolaryngology/Head and Neck Surgery, Second Affiliated Hospital of Harbin Medical
University, Harbin, 150081, P. R. China; Phone: +86-451-86296837; E-mail: 19661994@ems.hrbmu.edu.cn